12/16
01:29 pm
aim
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B [Globe and Mail, The (Toronto, Canada)]
Low
Report
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B [Globe and Mail, The (Toronto, Canada)]
12/10
09:00 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Low
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
12/1
09:13 am
aim
AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series [Yahoo! Finance]
Medium
Report
AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series [Yahoo! Finance]
12/1
08:55 am
aim
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
Low
Report
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
11/18
04:12 pm
aim
AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59 [Seeking Alpha]
Neutral
Report
AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59 [Seeking Alpha]
11/18
08:55 am
aim
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
Medium
Report
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
11/10
10:01 am
aim
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer [Yahoo! Finance]
11/10
08:55 am
aim
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
Medium
Report
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
11/4
09:05 am
aim
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
High
Report
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
11/3
08:55 am
aim
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
Medium
Report
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
10/20
09:15 am
aim
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
Low
Report
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
10/3
08:08 am
aim
AIM ImmunoTech (NYSE:AIM) had its price target lowered by analysts at Ascendiant Capital Markets from $150.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
AIM ImmunoTech (NYSE:AIM) had its price target lowered by analysts at Ascendiant Capital Markets from $150.00 to $24.00. They now have a "buy" rating on the stock.